HUP0003546A2 - Kompozíciók taxánok orális adagolására embereknek - Google Patents

Kompozíciók taxánok orális adagolására embereknek

Info

Publication number
HUP0003546A2
HUP0003546A2 HU0003546A HUP0003546A HUP0003546A2 HU P0003546 A2 HUP0003546 A2 HU P0003546A2 HU 0003546 A HU0003546 A HU 0003546A HU P0003546 A HUP0003546 A HU P0003546A HU P0003546 A2 HUP0003546 A2 HU P0003546A2
Authority
HU
Hungary
Prior art keywords
taxane
bioavailability
compositions
human patients
orally
Prior art date
Application number
HU0003546A
Other languages
English (en)
Inventor
Samuel Broder
Kenneth L. Duchin
Sami Selim
Original Assignee
Baker Norton Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharmaceuticals, Inc. filed Critical Baker Norton Pharmaceuticals, Inc.
Publication of HUP0003546A2 publication Critical patent/HUP0003546A2/hu
Publication of HUP0003546A3 publication Critical patent/HUP0003546A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány lehetővé teszi antineoplasztikus taxánok orális adagolásáttaxánra reagáló betegségekben szenvedő pácienseknekbiohozzáférhetőséget fokozó anyagokkal együtt. Taxánként előnyösenpaklitaxelt, biohozzáférhetőséget fokozó anyagként pedig előnyösenciklosporint, célszerűen ciklosporin A-t használnak. A találmányértelmében valamilyen taxánt és egy biohozzáférhetőséget elősegítőanyagot, előnyösen valamilyen ciklosporint együtt alkalmaznak taxánrareagáló betegségek gyógyítására alkalmas, orálisan adagolhatógyógyászati készítmény előállítására. A találmány oltalmi körekiterjed taxánokat és biohozzáférhetőséget fokozó anyagot együtttartalmazó, orálisan adagolható gyógyászati készítményekre is. Ó
HU0003546A 1997-05-27 1998-04-22 Compositions for administering taxanes orally to human patients HUP0003546A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27

Publications (2)

Publication Number Publication Date
HUP0003546A2 true HUP0003546A2 (hu) 2002-11-28
HUP0003546A3 HUP0003546A3 (en) 2002-12-28

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003546A HUP0003546A3 (en) 1997-05-27 1998-04-22 Compositions for administering taxanes orally to human patients

Country Status (23)

Country Link
EP (1) EP0994706B1 (hu)
JP (1) JP2002500667A (hu)
KR (1) KR100615783B1 (hu)
CN (2) CN1550231A (hu)
AR (1) AR012731A1 (hu)
AT (1) ATE308365T1 (hu)
AU (1) AU7130098A (hu)
BR (1) BR9809694A (hu)
CA (1) CA2290446C (hu)
CZ (1) CZ9904244A3 (hu)
DE (1) DE69832173T2 (hu)
DK (1) DK0994706T3 (hu)
ES (1) ES2247690T3 (hu)
HK (1) HK1026637A1 (hu)
HU (1) HUP0003546A3 (hu)
IL (2) IL132992A0 (hu)
NO (1) NO995812L (hu)
PL (1) PL337064A1 (hu)
RU (1) RU2205005C2 (hu)
SK (1) SK157599A3 (hu)
UA (1) UA74767C2 (hu)
WO (1) WO1998053811A1 (hu)
ZA (1) ZA984268B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1998058927A1 (en) * 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE60045114D1 (de) 1999-05-17 2010-11-25 Cancer Res Ventures Ltd Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
CN1450923A (zh) * 1999-10-27 2003-10-22 巴克·诺顿药物有限公司 给病人口服给予紫杉烷的方法和组合物
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
SI1372636T1 (sl) * 2001-02-28 2006-12-31 Bristol Myers Squibb Co Metronomsko odmerjanje taksanov za inhibiranje tumorske rasti
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP2438047B1 (en) * 2009-06-02 2014-07-30 Nikan Pharmaceuticals, LLC Antagonism of human formyl peptide receptor for treatment of disease
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
IL305727A (en) * 2021-03-17 2023-11-01 Dompe Farm Spa C5AR1 inhibitors to treat a hypersensitivity reaction to TAXANES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
JP2783680B2 (ja) * 1991-01-11 1998-08-06 ラボラトワール、グラクソ、ソシエテ、アノニム アクリジン誘導体
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
SI9520078B (sl) * 1994-07-26 1998-12-31 Indena S.P.A. Polsintetski taksani z antitumorsko aktivnostjo
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
EP0831870A4 (en) * 1995-06-07 1998-09-16 Avmax Inc USE OF ESSENTIAL OILS TO INCREASE THE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP0822815A4 (en) * 1996-01-31 1998-04-01 Bristol Myers Squibb Co PROCESS FOR MAKING ORAL-LIKE TAXANES ACTIVE FROM THE PHARMACEUTICAL VIEW
JP2000512997A (ja) * 1996-06-17 2000-10-03 イーライ・リリー・アンド・カンパニー 薬物耐性および多薬物耐性調節物質
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
ATE327735T1 (de) * 1998-04-01 2006-06-15 Jagotec Ag Taxan-mikroemulsionen

Also Published As

Publication number Publication date
JP2002500667A (ja) 2002-01-08
HUP0003546A3 (en) 2002-12-28
RU2205005C2 (ru) 2003-05-27
CA2290446A1 (en) 1998-12-03
AR012731A1 (es) 2000-11-08
EP0994706B1 (en) 2005-11-02
UA74767C2 (en) 2006-02-15
ZA984268B (en) 1999-06-23
BR9809694A (pt) 2000-10-03
DK0994706T3 (da) 2006-03-06
CA2290446C (en) 2008-01-29
KR100615783B1 (ko) 2006-08-25
SK157599A3 (en) 2002-10-08
IL132992A0 (en) 2001-03-19
DE69832173T2 (de) 2006-08-03
EP0994706A4 (en) 2001-05-16
NO995812L (no) 2000-01-25
CN1261275A (zh) 2000-07-26
WO1998053811A1 (en) 1998-12-03
NO995812D0 (no) 1999-11-26
ATE308365T1 (de) 2005-11-15
KR20010013025A (ko) 2001-02-26
CZ9904244A3 (cs) 2001-10-17
EP0994706A1 (en) 2000-04-26
DE69832173D1 (de) 2005-12-08
HK1026637A1 (en) 2000-12-22
AU7130098A (en) 1998-12-30
PL337064A1 (en) 2000-07-31
ES2247690T3 (es) 2006-03-01
CN1550231A (zh) 2004-12-01
IL132992A (en) 2006-08-20

Similar Documents

Publication Publication Date Title
HUP0000299A1 (hu) Késleltetett hatóanyag-leadású gyógyszerkészítmények
HUP0003546A2 (hu) Kompozíciók taxánok orális adagolására embereknek
BR9607066A (pt) Método, composições e conjuntos para aumentar a biodisponibilidade oral de agentes farmacêuticos
EP1061915A4 (en) PHARMACEUTICAL FORMULATIONS OF TAXANES
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
RU2003121768A (ru) Способ, лекарственная форма и наборы для повышения пероральной биологической доступности фармацевтических агентов
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
HUP0003173A2 (hu) A GLP-1 vagy analógjainak alkalmazása szívizominfarktus kezelésére használható gyógyszerkészítmények előállítására
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
HUP0101017A2 (hu) Készítmény és eljárás szájon át adagolható vakcinák és gyógyászati hatóanyagok szisztémás bevitelére
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
HUP0301349A2 (hu) IL-11-tartalmú készítmények
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
HUP0203303A2 (hu) Készítmény taxánok humán betegeknek történő orális adagolására
KR970061244A (ko) 치매 치료용 약학 조성물
HUP0105481A2 (hu) Klaritromicint vagy származékait tartalmazó gyógyászati készítmények és eljárás előállításukra, valamint alkalmazásuk
WO2001074396A8 (en) Composition and method for promoting oral health
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
Kamimura et al. Drug therapy for depression in Japan
NZ516026A (en) Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents

Legal Events

Date Code Title Description
FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): DR. PALAGYI TIVADAR, DANUBIA SZABADALMI ES VEDJEGY IRODA KFT., HU

Representative=s name: SZENTPETERI ZSOLT, S.B.G. & K. SZABADALMI UEGY, HU

FH92 Termination of representative

Representative=s name: DR. PALAGYI TIVADAR, DANUBIA SZABADALMI ES VED, HU

HC9A Change of name, address

Owner name: IVAX RESEARCH, INC., US

Free format text: FORMER OWNER(S): BAKER NORTON PHARMACEUTICALS, INC., US

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished